<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="16468" end="16473" sStart="16239" offset="229" sid="r7.1.use.v.0829" wn="1" wnkey="use%2:34:01::" annotator="veweser" text="There was no significant correlation with duration of exposure (R 2= 0.126, regression coefficient = 0.00037, p = 0.39) or with dose or time since stopping drug (by weighted analysis of covariance using continuous variables)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="9749" end="9754" sStart="null" offset="124" sid="r7.1.use.v.0184" wn="1" wnkey="use%2:34:01::" annotator="cgozo" text="The equation was solved for i given the observed change in prevalence between decades and time elapsed (using the end of each time period)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="18585" end="18591" sStart="null" offset="208" sid="r11.strong.j.0247" wn="1" wnkey="strong%3:00:00::" annotator="vebatchelder" text="Furthermore, our estimates of percent incident cases of AR among exposed were highly correlated with duration of exposure and appeared homogeneous, suggesting a biologically relevant, strong, causal relationship." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="28369" end="28375" sStart="null" offset="20" sid="r11.strong.j.0794" wn="1" wnkey="strong%3:00:00::" annotator="anfahmy" text="These findings lend strong support to the view that fenfluramine and dexfenfluramine are potent causal factors in the development of both aortic and mitral valvular heart disease." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="25285" end="25291" sStart="null" offset="13" sid="r11.strong.j.0768" wn="1 6" wnkey="null" annotator="adelpriore" text="However, the strong, consistent relationship between the percent of incident cases of AR in each study and duration of exposure suggests that our estimates were reasonable and biologically relevant." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2261-3-5.anc" start="9955" end="9960" sStart="null" offset="0" sid="null" wn="4" wnkey="show%2:39:00::" annotator="carichter" text="These estimated incidence rates are &lt;b&gt;shown&lt;/b&gt; in table 2. As a conservative estimate for relative risk calculations, all the rates were pooled (as the unweighted mean of the calculated rates in table 2for men and women), recognizing that this will yield a higher &quot;unexposed&quot; rate than was likely present for the younger and predominantly female populations exposed to the anorexic drugs." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2261-3-5.anc" start="5740" end="5744" sStart="null" offset="0" sid="null" wn="6" wnkey="read%2:31:09::" annotator="cgozo" text="We first evaluated studies reporting echocardiographic prevalence of FDA-positive valvulopathy (mild or greater AR and moderate or greater MR) [ 2 ] among subjects who had taken either fenfluramine or dexfenfluramine (alone or in combination with phentermine) and in matched controls [ 7 8 9 10 11 12 13 14 ] . In most of these studies, echocardiograms were performed after the drugs had been discontinued and were &lt;b&gt;read&lt;/b&gt; without knowledge of prior drug exposure by multiple readers (table 1)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2261-3-5.anc" start="24482" end="24487" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="veweser" text="Our observation that incidence &lt;b&gt;rates&lt;/b&gt; estimated from both populations were of a similar magnitude supports the feasibility of this approach." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2261-3-5.anc" start="24482" end="24487" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="rstandig" text="Our observation that incidence &lt;b&gt;rates&lt;/b&gt; estimated from both populations were of a similar magnitude supports the feasibility of this approach." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2261-3-5.anc" start="24482" end="24487" sStart="null" offset="0" sid="null" wn="1 4" wnkey="null" annotator="jeneale" text="Our observation that incidence &lt;b&gt;rates&lt;/b&gt; estimated from both populations were of a similar magnitude supports the feasibility of this approach." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2261-3-5.anc" start="10130" end="10135" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="cgozo" text="These estimated incidence &lt;b&gt;rates&lt;/b&gt; are shown in table 2. As a conservative estimate for relative risk calculations, all the &lt;b&gt;rates&lt;/b&gt; were pooled (as the unweighted mean of the calculated &lt;b&gt;rates&lt;/b&gt; in table 2for men and women), recognizing that this will yield a higher &quot;unexposed&quot; &lt;b&gt;rate&lt;/b&gt; than was likely present for the younger and predominantly female populations exposed to the anorexic drugs." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2261-3-5.anc" start="24482" end="24487" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="cgozo" text="Our observation that incidence &lt;b&gt;rates&lt;/b&gt; estimated from both populations were of a similar magnitude supports the feasibility of this approach." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2261-3-5.anc" start="10130" end="10135" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="brubin" text="These estimated incidence &lt;b&gt;rates&lt;/b&gt; are shown in table 2. As a conservative estimate for relative risk calculations, all the &lt;b&gt;rates&lt;/b&gt; were pooled (as the unweighted mean of the calculated &lt;b&gt;rates&lt;/b&gt; in table 2for men and women), recognizing that this will yield a higher &quot;unexposed&quot; &lt;b&gt;rate&lt;/b&gt; than was likely present for the younger and predominantly female populations exposed to the anorexic drugs." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2261-3-5.anc" start="24482" end="24487" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" annotator="brubin" text="Our observation that incidence &lt;b&gt;rates&lt;/b&gt; estimated from both populations were of a similar magnitude supports the feasibility of this approach." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2261-3-5.anc" start="24482" end="24487" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="bpassonneau" text="Our observation that incidence &lt;b&gt;rates&lt;/b&gt; estimated from both populations were of a similar magnitude supports the feasibility of this approach." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="18948" end="18953" sStart="null" offset="39" sid="r9.paper.n.0637" wn="5" wnkey="paper%1:10:02::" annotator="veweser" text="Using the data provided in the paper, a valve-specific analysis may be performed comparing incidence of aortic and mitral disease in those exposed for 4 months or longer versus all others." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="6348" end="6354" sStart="null" offset="79" sid="r8.number.n.0417" wn="1" wnkey="number%1:07:00::" annotator="veweser" text="Since only one study had performed echocardiography on a substantial number of subjects prior to initiation of the diet drugs [ 11 ] , some means of estimating and correcting for the baseline prevalence in the other studies was necessary." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="6913" end="6919" sStart="null" offset="52" sid="r8.number.n.0740" wn="7 1" wnkey="null" annotator="cgozo" text="Any cases observed beyond this background number were considered &quot;new&quot; or incident cases." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="11403" end="11409" sStart="null" offset="13" sid="r8.number.n.0472" wn="1" wnkey="number%1:07:00::" annotator="cgozo" text="The observed number of &quot;incident&quot; cases of AR or MR in the exposed group was calculated as the total number of cases minus the number expected at baseline (estimated from the prevalence in the unexposed control group in each study)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="27448" end="27453" sStart="null" offset="358" sid="r8.1.great.j.0132" wn="1" wnkey="great%5:00:01:large:00" annotator="cgozo" text="Indeed, the most recently published study (which did not suffer from measurement bias) showed a high prevalence (30%) of AR in persons taking fenfluramine or dexfenfluramine at the time of the echocardiogram, similar to the older prevalence studies [ 15 ] . Regarding the potential reversibility of valve dysfunction, great caution must be exercised in assuming any substantial reversal of valvular plaques, as recent pathological studies suggest a progressive nature to these lesions [ 33 ] . Furthermore, limited, early apparent echocardiographic improvement of acute rheumatic carditis has also been recently demonstrated [ 34 ] . The early improvement seen in this setting certainly does not preclude later progression of rheumatic valvular heart disease." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="24106" end="24111" sStart="null" offset="139" sid="r10.find.v.0963" wn="8" wnkey="find%2:36:00::" annotator="cgozo" text="The only studies to perform repeated echocardiograms (separated by one year in both) in large numbers of unexposed persons found either no net progression or net regression in their control groups [ 24 25 ] . Because these studies did not report usable direct measures of incidence, we made several assumptions to estimate unexposed incidence using raw data from the Framingham study and from the studies reviewed here." />
    <s path="file:/C:/OANC/data/written_2/technical/biomed/1471-2261-3-5.anc" start="27478" end="27487" sStart="null" offset="0" sid="null" wn="1" wnkey="exercise%2:34:00::" annotator="veweser" text="Indeed, the most recently published study (which did not suffer from measurement bias) showed a high prevalence (30%) of AR in persons taking fenfluramine or dexfenfluramine at the time of the echocardiogram, similar to the older prevalence studies [ 15 ] . Regarding the potential reversibility of valve dysfunction, great caution must be &lt;b&gt;exercised&lt;/b&gt; in assuming any substantial reversal of valvular plaques, as recent pathological studies suggest a progressive nature to these lesions [ 33 ] . Furthermore, limited, early apparent echocardiographic improvement of acute rheumatic carditis has also been recently demonstrated [ 34 ] . The early improvement seen in this setting certainly does not preclude later progression of rheumatic valvular heart disease." />
    <s path="file:/C:/OANC/data/written_2/technical/biomed/1471-2261-3-5.anc" start="27478" end="27487" sStart="null" offset="0" sid="null" wn="2" wnkey="exercise%2:41:00::" annotator="cgozo" text="Indeed, the most recently published study (which did not suffer from measurement bias) showed a high prevalence (30%) of AR in persons taking fenfluramine or dexfenfluramine at the time of the echocardiogram, similar to the older prevalence studies [ 15 ] . Regarding the potential reversibility of valve dysfunction, great caution must be &lt;b&gt;exercised&lt;/b&gt; in assuming any substantial reversal of valvular plaques, as recent pathological studies suggest a progressive nature to these lesions [ 33 ] . Furthermore, limited, early apparent echocardiographic improvement of acute rheumatic carditis has also been recently demonstrated [ 34 ] . The early improvement seen in this setting certainly does not preclude later progression of rheumatic valvular heart disease." />
    <s path="file:/C:/OANC/data/written_2/technical/biomed/1471-2261-3-5.anc" start="27478" end="27487" sStart="null" offset="0" sid="null" wn="1" wnkey="exercise%2:34:00::" annotator="brubin" text="Indeed, the most recently published study (which did not suffer from measurement bias) showed a high prevalence (30%) of AR in persons taking fenfluramine or dexfenfluramine at the time of the echocardiogram, similar to the older prevalence studies [ 15 ] . Regarding the potential reversibility of valve dysfunction, great caution must be &lt;b&gt;exercised&lt;/b&gt; in assuming any substantial reversal of valvular plaques, as recent pathological studies suggest a progressive nature to these lesions [ 33 ] . Furthermore, limited, early apparent echocardiographic improvement of acute rheumatic carditis has also been recently demonstrated [ 34 ] . The early improvement seen in this setting certainly does not preclude later progression of rheumatic valvular heart disease." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="5854" end="5861" sStart="null" offset="27" sid="r10.control.n.0875" wn="4" wnkey="control%1:09:02::" annotator="cgozo" text="In some studies, control subjects were derived from patients assigned to placebo in a formal randomized trial of fenfluramine or dexfenfluramine." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="10893" end="10900" sStart="null" offset="293" sid="r10.control.n.0724" wn="4" wnkey="control%1:09:02::" annotator="brubin" text="The second data set used to estimate unexposed incidence rates was the control groups of the studies listed in table 1. Cases of FDA-positive AR and MR reported in the control groups were assumed to have arisen between age 40 and the average age of the control group in each study." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="11950" end="11958" sStart="null" offset="191" sid="r10.control.n.0502" wn="4" wnkey="control%1:09:02::" annotator="anfahmy" text="The expected number of cases in the exposed population (for Poisson analyses) was calculated as the incidence rate (per year) determined from the pooled rate in controls (obtained as described above) multiplied by the duration of exposure (in years)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="137" end="148" sStart="null" offset="94" sid="r11.combination.n.0430" wn="1" wnkey="combination%1:14:00::" annotator="vebatchelder" text="Since the initial report by Connolly, et al [ 1 ] of valvulopathy in women taking the combination of fenfluramine and phentermine (fen-phen), controversy has surrounded the issue of associated risk." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="796" end="808" sStart="null" offset="530" sid="r11.combination.n.0280" wn="1" wnkey="combination%1:14:00::" annotator="vebatchelder" text="Initial reports of remarkably high prevalence of aortic and mitral regurgitation (AR and MR) as assessed by echocardiography in five separate populations [ 2 ] were subsequently supported by most [ 3 4 5 ] but not all investigators [ 6 ] . These uncontrolled reports were soon followed by a series of studies in which prevalence of echocardiographically-defined AR and MR were assessed in persons who had taken fenfluramine, dexfenfluramine, phentermine, or combinations of these medications and compared to unexposed, matched control populations [ 7 8 9 10 11 12 13 14 15 ] . The most recent of these studies found 30% of persons currently taking fenfluramine or dexfenfluramine had mild or greater AR or moderate or greater MR, similar to the very high prevalence reported in older studies [ 15 ] . The only prospective study found a significant, exposure-related increase in the risk of clinically diagnosed valve disease among users of fenfluramine and dexfenfluramine, but not phentermine [ 16 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2261-3-5.anc" start="5525" end="5536" sStart="null" offset="270" sid="r11.combination.n.0417" wn="7" wnkey="combination%1:04:00::" annotator="adelpriore" text="We first evaluated studies reporting echocardiographic prevalence of FDA-positive valvulopathy (mild or greater AR and moderate or greater MR) [ 2 ] among subjects who had taken either fenfluramine or dexfenfluramine (alone or in combination with phentermine) and in matched controls [ 7 8 9 10 11 12 13 14 ] . In most of these studies, echocardiograms were performed after the drugs had been discontinued and were read without knowledge of prior drug exposure by multiple readers (table 1)." />
  </sentences>
</list>